Drug Profile
Tc 99m NC 100668
Alternative Names: 99mTc-NC100668; NC100668; Tc-99m-NC100668Latest Information Update: 11 Sep 2006
Price :
$50
*
At a glance
- Originator GE Healthcare
- Class Oligopeptides; Organotechnetium compounds; Radiopharmaceutical diagnostics
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 11 Sep 2006 No development reported - Phase-II for Thrombosis (diagnosis) in United Kingdom (unspecified route)
- 16 Apr 2004 Amersham has merged with GE Medical Systems to form GE Healthcare
- 08 Oct 2002 Phase-II clinical trials in Thrombosis (diagnosis) in United Kingdom (unspecified route)